Idefirix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Idefirix market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the rising incidence of allergic diseases, increased drug dosages, a higher prevalence of chronic diseases, growing demand for organ transplants, and the increasing prevalence and incidence of kidney diseases.

Growth during the market's forecast period can be credited to the rising volumes of kidney transplant waiting lists, greater awareness about organ donation, increased research and development activities, a growing number of procedures and FDA approvals, and heightened awareness of antibody-mediated rejection. Key trends anticipated during the forecast period include advancements in antibody-cleaving enzyme technology, increased investments in transplant immunology research, collaborations with transplant centers for clinical adoption, a stronger emphasis on personalized medicine, and government initiatives promoting organ transplantation.

The rising prevalence and incidence of kidney diseases is expected to drive the growth of the idefirix market in the future. Kidney diseases are conditions that impair the kidneys’ structure or function, reducing their ability to filter waste and maintain fluid balance in the body. Factors such as an aging population, increasing rates of diabetes and hypertension, lifestyle habits, and genetic predispositions contribute to the growing prevalence and incidence of kidney diseases. Idefirix, an innovative immunoglobulin G (IgG)-degrading enzyme therapy, aids kidney disease patients by allowing highly sensitized individuals to undergo life-saving kidney transplants by effectively reducing donor-specific antibodies that could otherwise lead to transplant rejection. For example, in June 2023, a report by Kidney Research, a UK-based research organization, projected the incidence of acute kidney injury to rise from approximately 615,000 cases in 2022 to 637,000 cases by 2033. Consequently, the increasing prevalence and incidence of kidney diseases is boosting the growth of the idefirix market.

A key trend in the idefirix market is the focus on developing innovative solutions, such as desensitization treatments, to assist highly sensitized kidney transplant patients. Desensitization treatments are medical procedures that remove or diminish harmful antibodies, enabling transplant recipients to receive organs from otherwise incompatible donors. For instance, in July 2023, Hansa Biopharma, a Sweden-based biopharmaceutical company, announced that the Australian Therapeutic Goods Administration (TGA) approved Idefirix (imlifidase) as a desensitization treatment for highly sensitized kidney transplant patients. This approval allows these patients to receive kidney transplants from both living and deceased donors by reducing or removing harmful anti-donor antibodies that would otherwise prevent transplantation. Based on positive results from Hansa Biopharma's phase 2 studies, this approval represents a significant advancement in improving transplant options for highly sensitized patients in Australia.

In January 2022, Hansa Biopharma AB, a Sweden-based biopharmaceutical company, partnered with Asklepios Biopharmaceutical Inc. (AskBio) to evaluate imlifidase as a pre-treatment for Pompe disease gene therapy. This partnership aims to assess the feasibility of using Imlifidase (Idefirix) as a pre-treatment for patients with neutralizing antibodies (NAbs) to adeno-associated virus (AAV) undergoing gene therapy for Pompe disease. The collaboration addresses a critical challenge in gene therapy by overcoming antibody-mediated barriers, thus enabling successful treatment outcomes. Asklepios Biopharmaceutical (AskBio) is a UK-based gene therapy company specializing in developing medicines using adeno-associated virus (AAV) vectors for genetic diseases.

The key company operating in the idefirix market is Hansa Biopharma AB.

Europe was the largest region in the idefirix market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in idefirix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Idefirix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Idefirix (imlifidase) is an enzyme-based medication developed to lower donor-specific antibodies in highly sensitized kidney transplant patients, facilitating successful organ transplantation. It is used to desensitize patients awaiting kidney transplants by cleaving IgG antibodies, thereby improving compatibility with available donors.

The primary patient demographics for idefirix include pediatric and adult patients. Pediatric patients consist of children or adolescents who require medical care suited to their developmental and physiological needs. It is utilized in applications such as kidney transplantation and desensitization protocols. The end users of Idefirix are hospitals, specialized clinics, and home healthcare providers. Its distribution occurs through channels such as direct sales and pharmacies.

The idefirix market research report is one of a series of new reports that provides idefirix market statistics, including idefirix industry global market size, regional shares, competitors with a idefirix market share, detailed idefirix market segments, market trends and opportunities, and any further data you may need to thrive in the idefirix industry. This idefirix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The idefirix market consists of sales of lyophilized powders and injectable solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.